Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.124
Buy
RSI(14)
55.632
Neutral
STOCH(KDJ)(9,3,3)
78.534
Neutral
ATR(14)
0.848
Low Volatility
CCI(14)
111.509
Buy
Williams %R
14.035
Overbought
TRIX(12,20)
0.049
Sell
StochRSI(14)
65.781
Buy
Amphastar Pharmaceuticals Inc
AMPH27.120USD
+0.310+1.16%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.26BMarket Cap
11.50P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Amphastar Pharmaceuticals Inc
Currency: USD Updated: 2025-12-26Key Insights
Amphastar Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.71.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amphastar Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
31.714
Target Price
+21.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Amphastar Pharmaceuticals Inc Highlights
StrengthsRisks
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 46.69% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 731.97M.
Fairly Valued
The company’s latest PE is 11.50, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.97M shares, increasing 0.05% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 276.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of Amphastar Pharmaceuticals Inc is 8.81, ranking 33/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 191.84M, representing a year-over-year increase of 0.33%, while its net profit experienced a year-over-year increase of 57.09%.
Score
Financials
6.86
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
9.65
Shareholder Returns
7.53
Amphastar Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of Amphastar Pharmaceuticals Inc is 8.00, ranking 35/158 in the Pharmaceuticals industry. Its current P/E ratio is 11.50, which is 168.32% below the recent high of 30.86 and 36.28% above the recent low of 7.33.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 30/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of Amphastar Pharmaceuticals Inc is 7.67, ranking 93/158 in the Pharmaceuticals industry. The average price target for Amphastar Pharmaceuticals Inc is 31.00, with a high of 38.00 and a low of 25.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
31.714
Target Price
+21.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Amphastar Pharmaceuticals Inc
AMPH
6
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of Amphastar Pharmaceuticals Inc is 8.52, ranking 66/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 28.25 and the support level at 25.57, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
26.860
Buy
MA10
26.406
Buy
MA20
26.532
Buy
MA50
25.802
Buy
MA100
26.716
Buy
MA200
25.611
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of Amphastar Pharmaceuticals Inc is 7.00, ranking 44/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.20%, representing a quarter-over-quarter increase of 0.47%. The largest institutional shareholder is The Vanguard, holding a total of 2.61M shares, representing 5.68% of shares outstanding, with 10.87% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)
TD Asset Management Inc.
Dimensional Fund Advisors, L.P.
State Street Investment Management (US)
Fuller & Thaler Asset Management Inc.
Boston Trust Walden Company
Epoch Investment Partners, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of Amphastar Pharmaceuticals Inc is 6.34, ranking 55/158 in the Pharmaceuticals industry. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.89
VaR
+3.51%
240-Day Maximum Drawdown
+46.41%
240-Day Volatility
+41.74%
Return
Best Daily Return
60 days
+8.70%
120 days
+14.91%
5 years
+15.39%
Worst Daily Return
60 days
-5.37%
120 days
-5.37%
5 years
-21.15%
Sharpe Ratio
60 days
+0.38
120 days
+0.98
5 years
+0.42
Risk Assessment
Maximum Drawdown
240 days
+46.41%
3 years
+68.28%
5 years
+68.28%
Return-to-Drawdown Ratio
240 days
-0.61
3 years
-0.08
5 years
+0.15
Skewness
240 days
+0.96
3 years
+0.49
5 years
-0.14
Volatility
Realised Volatility
240 days
+41.74%
5 years
+40.91%
Standardised True Range
240 days
+3.65%
5 years
+4.55%
Downside Risk-Adjusted Return
120 days
+215.84%
240 days
+215.84%
Maximum Daily Upside Volatility
60 days
+37.69%
Maximum Daily Downside Volatility
60 days
+25.89%
Liquidity
Average Turnover Rate
60 days
+1.12%
120 days
+1.19%
5 years
--
Turnover Deviation
20 days
+33.37%
60 days
+14.46%
120 days
+21.61%
Peer Comparison
Pharmaceuticals
Amphastar Pharmaceuticals Inc
AMPH
7.97 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Amphastar Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Amphastar Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Amphastar Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Amphastar Pharmaceuticals Inc?
To generate the financial health score of Amphastar Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Amphastar Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Amphastar Pharmaceuticals Inc.
How do we generate the company valuation score of Amphastar Pharmaceuticals Inc?
To generate the company valuation score of Amphastar Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Amphastar Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Amphastar Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Amphastar Pharmaceuticals Inc.
How do we generate the earnings forecast score of Amphastar Pharmaceuticals Inc?
To calculate the earnings forecast score of Amphastar Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Amphastar Pharmaceuticals Inc’s future.
How do we generate the price momentum score of Amphastar Pharmaceuticals Inc?
When generating the price momentum score for Amphastar Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Amphastar Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Amphastar Pharmaceuticals Inc.
How do we generate the institutional confidence score of Amphastar Pharmaceuticals Inc?
To generate the institutional confidence score of Amphastar Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Amphastar Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Amphastar Pharmaceuticals Inc.
How do we generate the risk management score of Amphastar Pharmaceuticals Inc?
To assess the risk management score of Amphastar Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Amphastar Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Amphastar Pharmaceuticals Inc.
